• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Frequency raises $32m in Series A for hearing loss therapy

April 11, 2017 By Sarah Faulkner

Frequency raises $32m in Series A for hearing loss therapyFrequency Therapeutics said today that it closed a $32 million Series A round, led by CoBro Ventures. Morningside Ventures, Emigrant Capital Corp., Korean Investment Partnership, Alexandria Real Estate Equities and other groups also invested in the round.

The company has developed a proprietary combination of small molecule drugs that they plan to inject in the ear, stimulating the regrowth of sensory hair cells to treat chronic noise-induced hearing loss.

The team has figured out how to activate progenitor cells – mature stem cells that can proliferate into different types of cells – in an attempt to recover hearing.

The company plans to use a clinically-established injection into the middle ear of a slow-release gel, in a 3-minute office procedure that’s been used for years to administer drugs to treat ear infections.

“Bob Langer and Jeff Karp’s vision is to gain much of the same effect as gene therapy and CRISPR by using small molecules, which we believe are safer and allow for easier delivery. Our data is very compelling and we are excited to be moving to the clinic in the next 12 to 18 months,” chairman Marc Cohen said in prepared remarks. “Hearing loss is not just a symptom of aging, but an indication that affects a significant percentage of the world’s population in people of all ages. The U.S. loses on average $56 billion in annual productivity due to the complications associated with chronic noise-induced hearing loss alone.”

“With no effective therapy available, this presents an enormous market opportunity and we believe there is even broader potential in indications beyond hearing loss with the further development of the PCA platform. Frequency is building a next-generation regenerative medicine company with a truly breakthrough approach designed to awaken the body’s innate ability to restore function to damaged or diseased tissues,” co-founder, president & CEO David Lucchino added.

Filed Under: Drug-Device Combinations, Featured, Regenerative Medicine, Stem Cells, Wall Street Beat Tagged With: Frequency Therapeutics

IN CASE YOU MISSED IT

  • Eitan Medical lands FDA clearance for infusion pump system upgrade
  • Senseonics announces $50M from stock offering
  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Locate Bio lands FDA breakthrough nod for bone infection device
  • PerkinElmer to acquire Oxford Immunotec

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS